Journal
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
Volume 4, Issue 1, Pages 31-37Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13346-013-0180-9
Keywords
Extracellular vesicles; Exosome; RNAi; miRNA; siRNA; Drug delivery system
Funding
- Ministry of Education, Culture, Sports, Science and Technology
- National Cancer Center Research and Development Fund
- Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio)
- Project for Development of Innovative Research on Cancer Therapeutics
- Japan Society for the Promotion of Science (JSPS) through the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program)
- Council for Science and Technology Policy (CSTP)
Ask authors/readers for more resources
RNA interference (RNAi) is an important avenue for target-specific gene silencing that is mainly performed by either small interfering RNAs (siRNAs) or microRNAs (miRNAs). This novel method is rapidly becoming a powerful tool for gene therapy. However, the rapid degradation of siRNAs and miRNAs and the limited duration of their action in vivo call for an efficient delivery technology. Recently, increasing attention has been paid to the use of extracellular vesicles (EVs) as delivery systems. The use of EVs as small RNA carriers has multiple advantages over conventional delivery systems. In this review, we summarize recent findings regarding the potential application of EVs as small RNA delivery systems. Moreover, we focus on some of the obstacles to EV-based therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
